Vontobel Holding’s C4 Therapeutics CCCC Stock Holding History

Vontobel Holding’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,000	Closed	-$644K	–	1065
2021 Q4	$644K	Hold	20,000	–	–	0.01%	756
2021 Q3	$894K	Hold	20,000	–	–	0.01%	649
2021 Q2	$757K	Hold	20,000	–	–	0.01%	662
2021 Q1	$740K	Hold	20,000	–	–	0.01%	584
2020 Q4	$663K	Buy	+20,000	New	+$580K	﹤0.01%	600

Other funds holding CCCC

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vontobel Holding's CCCC Position: Q1 2022 in Review

Vontobel Holding sold out of C4 Therapeutics (CCCC) in Q1 2022, closing a stake of 20,000 shares — an estimated $644K sold.

Vontobel Holding first reported a position in CCCC in Q4 2020 and held it in 5 quarters. The position peaked at $894K in Q3 2021. 125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

Vontobel Holding reported no remaining C4 Therapeutics position as of Q1 2022 after selling out during the quarter.
Vontobel Holding sold 20,000 C4 Therapeutics shares in Q1 2022, an estimated $644K.
Vontobel Holding first reported a position in C4 Therapeutics in Q4 2020 and held it in 5 quarters.
Vontobel Holding's C4 Therapeutics position peaked at $894K in Q3 2021.
125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Vontobel Holding's 13F filing for Q1 2022, filed 13 May 2022.